Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

A tech-led rebound after the Federal Reserves rate hike, aided by falling oil prices and Treasury yields, is driving attention to QQQ. Traders are split between viewing the move as a durable relief rally and seeing it as an overbought, algorithm-driven short squeeze vulnerable to volatility around the Bank of Japan decision and options expiration.

Anticipation of Starship Flight 14, now targeted for as early as Sept. 28 after another delay, is the dominant catalyst, with traders debating whether a successful mission could support momentum. Bulls also point to index-rebalance flows and SpaceXs Starlink expansion, while bears focus on launch risk, elevated valuation and upcoming lockup-related share supply.

A broad semiconductor and AI-stock rebound, as concerns about slowing AI spending eased and chip-demand optimism returned, is driving AMD attention alongside strong bullish momentum and call activity. Traders are debating whether the move can extend toward a breakout, while others flag stretched valuation, overbought conditions, and the risk of a pullback.

Barclays upgraded outlook, supported by a physician survey and anticipation of Iovances IOV-LUN-202 lung-cancer update, is driving attention alongside expectations for revised guidance and continued Amtagvi commercialization. Traders are broadly bullish on the companys pipeline and potential short covering, though some caution that profit-taking, options positioning, and clinical uncertainty could bring volatility.

Rigetti is drawing attention after signing a definitive U.S. Department of Commerce agreement to fund superconducting quantum-computing research in exchange for a minority equity stake. Traders view the government backing as validation and a potential momentum catalyst for the broader quantum sector, while skeptics focus on share dilution, valuation, limited revenue, and execution risk.

The upcoming XP-8121 program overview is driving attention, with management expected to outline the pivotal Phase 3 design and commercialization strategy for its once-weekly injectable levothyroxine candidate. Traders are divided: bullish participants see major long-term potential alongside growing Recorlev sales, while skeptics view the projected 2030 launch timeline and added trial costs as limiting near-term upside; buyout speculation remains unconfirmed.

Renewed enthusiasm for AI infrastructure and server demand is lifting SMCI alongside peers, with traders highlighting its low valuation, expected backlog growth, and heavy call activity as potential short-squeeze fuel. Bulls view the move as a breakout after prolonged range-bound trading, while skeptics point to possible ATM dilution, options-driven volatility, and repeated resistance near recent highs.

Rallying Hyperliquid (HYPE) prices and continued accumulation of HYPE in the companys digital-asset treasury have made PURR a closely watched equity proxy for the ecosystem. Traders are broadly bullish on further upside and potential short covering, while others warn that the move is overextended and debate dilution, token-unlock risk, and uncertain U.S. regulatory access.

Reported exploratory talks for SK Hynix to use Intels Ohio facilities or form a joint venture for U.S. memory-chip production are driving attention, with traders viewing the potential partnership as a boost to Intels foundry strategy amid strong AI-related memory demand. The community is broadly bullish and discussing short-covering and options-driven momentum, although skeptics note that SK Hynix says no specific plan or agreement has been finalized.

Strong post-earnings momentum and an improved outlook are driving attention, with traders highlighting Zetas AI-powered marketing growth and partnerships with Palantir, OpenAI and Snowflake. Bulls are also positioning ahead of Zeta Live and the next earnings report, while skeptics debate whether the rally is overextended and due for a pullback.